Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer “Moonshot” Launch Team Announced: Uncomfortable Ties To Anti-Industry Headlines

This article was originally published in RPM Report

Executive Summary

The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.

Advertisement

Related Content

Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus
Abraxane White Paper Distribution At ASCO Draws FDA Advertising Letter
Bristol De-Lists ABI Taxol Patent Under Settlement With Ivax
Ivax Generic Paclitaxel Clears FDA; Bristol Patent Case Pending In N.Y.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079916

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel